Kelly Francisco da Cunha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kelly Francisco da Cunha has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Jose Luiz Costa
Universidade Estadual de Campinas (UNICAMP)
9 shared publications - Karina Diniz Oliveira
Universidade Estadual de Campinas
3 shared publications - Ana Carolina Furiozo Arantes
Campinas Poison Control Center, University of Campinas (UNICAMP), Campinas, SP, 13083-859, Brazil; Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, 13083-859, Brazil
2 shared publications - Julia Martinelli Magalhães Kahl
Campinas Poison Control Center, School of Medical Sciences, University of Campinas , Campinas, SP 13083-888
2 shared publications Karina Diniz Oliveira
Campinas Poison Control Center, University of Campinas (UNICAMP), Campinas, SP, 13083-859, Brazil; Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, SP, 13083-859, Brazil
2 shared publicationsMarilia Santoro Cardoso
Faculty of Medical Sciences, University of Campinas , Tessália Vieira de Camargo 126, Cidade Universitária, Campinas, SP 13083-887
2 shared publications
Latest Publications
- 29 August 2023
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 47 (9) , 835-841
Development and validation of a sensitive LC–MS-MS method to quantify psilocin in authentic oral fluid samples
Psilocin is an active substance and dephosphorylated product of psilocybin formed after ingestion of mushrooms. The low stability caused by the quick oxidation of this analyte requires sensitive methods for its determination in biological matrices. In this work, we described a method development, optimization, and validation for the quantification of psilocin in authentic oral fluid samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Liquid-liquid extraction (LLE) was performed using 100 µL of oral fluid samples collected with Quantisal™ device and t-butyl methyl ether (MTBE) as the extraction solvent. The method showed acceptable performance, with limits of detection and quantification of 0.05 ng/mL, and the calibration model was achieved between 0.05 and 10 ng/mL. Bias and imprecision results were below -14.2% and 10.7%, respectively. Ionization suppression/enhancement were lower than -30.5%, and recovery was higher than 54.5%. Dilution integrity bias was below 14.4%. No endogenous and exogenous interferences were observed analyzing oral fluid from 10 different sources and 55 pharmaceuticals and drugs of abuse, respectively. No carryover was observed at 10 ng/mL. Psilocin was stable in oral fluid at -20°C, 4°C and 24°C up to 24, 72 and 24 h, respectively, with variations lower than 17.7%. The analyte was not stable after 3 freeze/thaw cycles, with variations between -73% and -60%. This suggests the instability of psilocin in oral fluid samples, which requires timely analysis, as soon as possible after the collection. The analyte remained stable in processed samples in autosampler (at 10°C) for up to 18 h. The method was successfully applied for the quantification of five authentic samples collected from volunteers attending parties and electronic music festivals. Psilocin concentrations ranged from 0.08 to 36.4 ng/mL. This is the first work to report psilocin concentrations in authentic oral fluid samples.
- 29 August 2023
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 47 (9) , 835-841
Development and validation of a sensitive LC–MS-MS method to quantify psilocin in authentic oral fluid samples
Psilocin is an active substance and dephosphorylated product of psilocybin formed after ingestion of mushrooms. The low stability caused by the quick oxidation of this analyte requires sensitive methods for its determination in biological matrices. In this work, we described a method development, optimization, and validation for the quantification of psilocin in authentic oral fluid samples by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Liquid-liquid extraction (LLE) was performed using 100 µL of oral fluid samples collected with Quantisal™ device and t-butyl methyl ether (MTBE) as the extraction solvent. The method showed acceptable performance, with limits of detection and quantification of 0.05 ng/mL, and the calibration model was achieved between 0.05 and 10 ng/mL. Bias and imprecision results were below -14.2% and 10.7%, respectively. Ionization suppression/enhancement were lower than -30.5%, and recovery was higher than 54.5%. Dilution integrity bias was below 14.4%. No endogenous and exogenous interferences were observed analyzing oral fluid from 10 different sources and 55 pharmaceuticals and drugs of abuse, respectively. No carryover was observed at 10 ng/mL. Psilocin was stable in oral fluid at -20°C, 4°C and 24°C up to 24, 72 and 24 h, respectively, with variations lower than 17.7%. The analyte was not stable after 3 freeze/thaw cycles, with variations between -73% and -60%. This suggests the instability of psilocin in oral fluid samples, which requires timely analysis, as soon as possible after the collection. The analyte remained stable in processed samples in autosampler (at 10°C) for up to 18 h. The method was successfully applied for the quantification of five authentic samples collected from volunteers attending parties and electronic music festivals. Psilocin concentrations ranged from 0.08 to 36.4 ng/mL. This is the first work to report psilocin concentrations in authentic oral fluid samples.
- 27 August 2023
- Published by Elsevier in Electrochimica Acta
- Vol. 467
Oxygen plasma-treated graphite sheet electrodes: A sensitive and disposable sensor for methamphetamines
- 27 August 2023
- Published by Elsevier in Electrochimica Acta
- Vol. 467
Oxygen plasma-treated graphite sheet electrodes: A sensitive and disposable sensor for methamphetamines
- 19 September 2022
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 47, 100475
In vitro metabolism of the new antifungal dapaconazole using liver microsomes
- 19 September 2022
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 47, 100475
In vitro metabolism of the new antifungal dapaconazole using liver microsomes
- 12 April 2022
- Published by Springer Nature in Forensic Toxicology
- Vol. 40 (2) , 322-331
High-sensitivity method for the determination of LSD and 2-oxo-3-hydroxy-LSD in oral fluid by liquid chromatography‒tandem mass spectrometry
- 12 April 2022
- Published by Springer Nature in Forensic Toxicology
- Vol. 40 (2) , 322-331
High-sensitivity method for the determination of LSD and 2-oxo-3-hydroxy-LSD in oral fluid by liquid chromatography‒tandem mass spectrometry
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108962
Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties
- 1 October 2021
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 227, 108962
Prevalence of new psychoactive substances (NPS) in Brazil based on oral fluid analysis of samples collected at electronic music festivals and parties
- Open Access
- 25 December 2020
- Published by Springer Nature in Forensic Toxicology
- Vol. 39 (1) , 179-197
Development and validation of quantitative analytical method for 50 drugs of antidepressants, benzodiazepines and opioids in oral fluid samples by liquid chromatography–tandem mass spectrometry
Purpose: We developed and validated a method for quantitative analysis of 50 psychoactive substances and metabolites (antidepressants, benzodiazepines and opioids) in oral fluid samples using simple liquid–liquid extraction procedure followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Method: Oral fluid samples were collected using Quantisal™ device and extracted by liquid–liquid extraction with 1.0 mL of methyl tert-butyl ether and then analyzed using LC–MS/MS. Results: The method attended method validation criteria, with limits of quantification as low as 0.5 and 1.0 ng/mL, and linearity between 0.5–50.0 ng/mL for antidepressants, 0.5–25.0 ng/mL for benzodiazepines and 1.0–50.0 ng/mL to opioids. During method validation, bias and imprecision values were not greater than 16 and 20%, respectively. Ionization suppression/enhancement bias results were not greater than 25%. No evidence of carryover was observed. Sample stability studies showed that almost all analytes were stable at 25 °C for 3 days and at 4 °C for 7 days. Freeze–thaw cycles stability showed that most antidepressants and opioids were stable under these conditions. Autosampler stability study showed that all analytes were stable for 24 h, except for nitrazepam and 7-aminoclonazepam. Thirty-eight authentic oral fluid samples were analyzed; 36.8% of the samples were positive for 2 drugs. Citalopram was the most common drug found, followed by venlafaxine. Conclusions: The method was validated according to international recommendations for the 50 analytes, showing low limits of quantification, good imprecision and bias values, using simple liquid–liquid extraction, and was successfully applied to authentic oral fluid samples analysis.
- 25 December 2020
- Published by Springer Nature in Forensic Toxicology
- Vol. 39 (1) , 179-197
Open AccessDevelopment and validation of quantitative analytical method for 50 drugs of antidepressants, benzodiazepines and opioids in oral fluid samples by liquid chromatography–tandem mass spectrometry
Purpose: We developed and validated a method for quantitative analysis of 50 psychoactive substances and metabolites (antidepressants, benzodiazepines and opioids) in oral fluid samples using simple liquid–liquid extraction procedure followed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). Method: Oral fluid samples were collected using Quantisal™ device and extracted by liquid–liquid extraction with 1.0 mL of methyl tert-butyl ether and then analyzed using LC–MS/MS. Results: The method attended method validation criteria, with limits of quantification as low as 0.5 and 1.0 ng/mL, and linearity between 0.5–50.0 ng/mL for antidepressants, 0.5–25.0 ng/mL for benzodiazepines and 1.0–50.0 ng/mL to opioids. During method validation, bias and imprecision values were not greater than 16 and 20%, respectively. Ionization suppression/enhancement bias results were not greater than 25%. No evidence of carryover was observed. Sample stability studies showed that almost all analytes were stable at 25 °C for 3 days and at 4 °C for 7 days. Freeze–thaw cycles stability showed that most antidepressants and opioids were stable under these conditions. Autosampler stability study showed that all analytes were stable for 24 h, except for nitrazepam and 7-aminoclonazepam. Thirty-eight authentic oral fluid samples were analyzed; 36.8% of the samples were positive for 2 drugs. Citalopram was the most common drug found, followed by venlafaxine. Conclusions: The method was validated according to international recommendations for the 50 analytes, showing low limits of quantification, good imprecision and bias values, using simple liquid–liquid extraction, and was successfully applied to authentic oral fluid samples analysis.
- 29 October 2020
- Published by Wiley in Drug Testing and Analysis
- Vol. 13 (3) , 664-678
Kinetic profile of N,N‐dimethyltryptamine and β‐carbolines in saliva and serum after oral administration of ayahuasca in a religious context
Ayahuasca is a beverage obtained from Banisteriopsis caapi plus Psychotria viridis. B. caapi contains the β‐carbolines harmine, harmaline, and tetrahydroharmine that are monoamine oxidase inhibitors and P. viridis contains N,N‐dimethyltryptamine (DMT) that is responsible for the visionary effects of the beverage. Ayahuasca use is becoming a global phenomenon, and the recreational use of DMT and similar alkaloids has also increased in recent years; such uncontrolled use can lead to severe intoxications. In this investigation, liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to study the kinetics of alkaloids over a 24 h period in saliva and serum of 14 volunteers who consumed ayahuasca twice a month in a religious context. We compared the area under the curve (AUC), maximum concentration (Cmax), time to reach Cmax (Tmax), mean residence time (MRT), and half‐life (t1/2), as well as the serum/saliva ratios of these parameters. DMT and β‐carboline concentrations (Cmax) and AUC were higher in saliva than in serum and the MRT was 1.5–3.0 times higher in serum. A generalized estimation equations (GEEs) model suggested that serum concentrations could be predicted by saliva concentrations, despite large individual variability in the saliva and serum alkaloid concentrations. The possibility of using saliva as a biological matrix to detect DMT, β‐carbolines, and their derivatives is very interesting because it allows fast noninvasive sample collection and could be useful for detecting similar alkaloids used recreationally that have considerable potential for intoxication.
- 29 October 2020
- Published by Wiley in Drug Testing and Analysis
- Vol. 13 (3) , 664-678
Kinetic profile of N,N‐dimethyltryptamine and β‐carbolines in saliva and serum after oral administration of ayahuasca in a religious context
Ayahuasca is a beverage obtained from Banisteriopsis caapi plus Psychotria viridis. B. caapi contains the β‐carbolines harmine, harmaline, and tetrahydroharmine that are monoamine oxidase inhibitors and P. viridis contains N,N‐dimethyltryptamine (DMT) that is responsible for the visionary effects of the beverage. Ayahuasca use is becoming a global phenomenon, and the recreational use of DMT and similar alkaloids has also increased in recent years; such uncontrolled use can lead to severe intoxications. In this investigation, liquid chromatography–tandem mass spectrometry (LC–MS/MS) was used to study the kinetics of alkaloids over a 24 h period in saliva and serum of 14 volunteers who consumed ayahuasca twice a month in a religious context. We compared the area under the curve (AUC), maximum concentration (Cmax), time to reach Cmax (Tmax), mean residence time (MRT), and half‐life (t1/2), as well as the serum/saliva ratios of these parameters. DMT and β‐carboline concentrations (Cmax) and AUC were higher in saliva than in serum and the MRT was 1.5–3.0 times higher in serum. A generalized estimation equations (GEEs) model suggested that serum concentrations could be predicted by saliva concentrations, despite large individual variability in the saliva and serum alkaloid concentrations. The possibility of using saliva as a biological matrix to detect DMT, β‐carbolines, and their derivatives is very interesting because it allows fast noninvasive sample collection and could be useful for detecting similar alkaloids used recreationally that have considerable potential for intoxication.
- 18 July 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (7) , 697-707
Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC–MS-MS
New psychoactive substances (NPS) are a major public health problem, primarily due to the increased number of acute poisoning cases. Detection of these substances is a challenge. The aim of this research was to develop and validate a sensitive screening method for 104 drugs of abuse, including synthetic cannabinoids, synthetic cathinones, fentanyl analogues, phenethylamines and other abused psychoactive compounds (i.e., THC, MDMA, LSD and their metabolites) in oral fluid by liquid chromatography–tandem mass spectrometry (LC–MS-MS). The Quantisal™ oral fluid device was used to collect oral fluid samples. The oral fluid–elution buffer mixture (500-μL sample) was extracted with t-butyl methyl ether, and chromatographic separation was performed on a Raptor™ biphenyl column (100 × 2.1 mm ID, 2.7 μm), with a total run time of 13.5 min. Limits of detection were established at three concentrations (0.05, 0.1 or 1 ng/mL) for most analytes, except for acetyl norfentanyl and mescaline (5 ng/mL). Matrix effects were generally 60%. The highest matrix effect was observed within the synthetic cannabinoid group (PB22, −55.5%). Lower recoveries were observed for 2C-T (47.2%) and JWH-175 (58.7%). Recoveries from the Quantisal™ device were also evaluated for all analytes (56.7–127%), with lower recoveries noted for 25I-NBOMe, valerylfentanyl and mCPP (56.7, 63.0 and 69.9%, respectively). Drug stability in oral fluid was evaluated at 15, 60 and 90 days and at 25, 4 and −20°C. As expected, greater stability was observed when samples were stored at −20°C, but even when frozen, some NPS (e.g., synthetic cannabinoids) showed more than 20% degradation. The method was successfully applied to the analysis of seven authentic oral fluid samples positive for 17 different analytes. The method achieved good sensitivity and simultaneous detection of a wide range of NPS.
- 18 July 2020
- Published by Oxford University Press (OUP) in Journal of Analytical Toxicology
- Vol. 44 (7) , 697-707
Screening of 104 New Psychoactive Substances (NPS) and Other Drugs of Abuse in Oral Fluid by LC–MS-MS
New psychoactive substances (NPS) are a major public health problem, primarily due to the increased number of acute poisoning cases. Detection of these substances is a challenge. The aim of this research was to develop and validate a sensitive screening method for 104 drugs of abuse, including synthetic cannabinoids, synthetic cathinones, fentanyl analogues, phenethylamines and other abused psychoactive compounds (i.e., THC, MDMA, LSD and their metabolites) in oral fluid by liquid chromatography–tandem mass spectrometry (LC–MS-MS). The Quantisal™ oral fluid device was used to collect oral fluid samples. The oral fluid–elution buffer mixture (500-μL sample) was extracted with t-butyl methyl ether, and chromatographic separation was performed on a Raptor™ biphenyl column (100 × 2.1 mm ID, 2.7 μm), with a total run time of 13.5 min. Limits of detection were established at three concentrations (0.05, 0.1 or 1 ng/mL) for most analytes, except for acetyl norfentanyl and mescaline (5 ng/mL). Matrix effects were generally 60%. The highest matrix effect was observed within the synthetic cannabinoid group (PB22, −55.5%). Lower recoveries were observed for 2C-T (47.2%) and JWH-175 (58.7%). Recoveries from the Quantisal™ device were also evaluated for all analytes (56.7–127%), with lower recoveries noted for 25I-NBOMe, valerylfentanyl and mCPP (56.7, 63.0 and 69.9%, respectively). Drug stability in oral fluid was evaluated at 15, 60 and 90 days and at 25, 4 and −20°C. As expected, greater stability was observed when samples were stored at −20°C, but even when frozen, some NPS (e.g., synthetic cannabinoids) showed more than 20% degradation. The method was successfully applied to the analysis of seven authentic oral fluid samples positive for 17 different analytes. The method achieved good sensitivity and simultaneous detection of a wide range of NPS.